Developer docs
API playgroundTry for free, no card

Search company profiles

Lionex Diagnostics & Therapeutics

Full company profile

uuid002osne

Namestring
Lionex Diagnostics & Therapeutics
Legal namestring
LIONEX GmbH
Websiteurl
lionex.de
Company typeenum
Private
Founded yearstring
-
Descriptiontext

LIONEX Diagnostics & Therapeutics GmbH is a privately held German biotech company headquartered in Braunschweig that develops and manufactures in-vitro diagnostic (IVD) products, research reagents and OEM lateral flow assays, with its strategic centre of gravity in tuberculosis (TB) and adjacent infectious disease and cancer biomarker detection. The company operates ISO 13485-certified manufacturing facilities (re-certified December 2024 by TÜV Rheinland) including CAT-I and CAT-II molecular biology laboratories with CAT-III access, and produces highly purified, endotoxin-free recombinant proteins using multiple expression systems (E. coli, insect cells, B. subtilis, Lactococcus lactis, M. smegmatis). Its flagship proprietary assets are the LIOFeron TB/LTBI Interferon Gamma Release Assay (IGRA) — featuring a unique antigen cocktail including alanine dehydrogenase for CD8+ T-cell stimulation — the LIODetect rapid lateral flow family (TB-ST, CRP, D-Dimer, Troponin I, COVID-19 IgG/IgM/Ag), and the patented LIOSpot TB ELISPOT test that differentiates latent from active TB. The company also holds exclusive global manufacturing and distribution rights to the EndoTrap family of endotoxin removal resins (acquired when Hyglos discontinued in December 2017) and offers EndoGrade endotoxin-free ovalbumin for vaccine research.

LIONEX monetizes through four distinct revenue streams: (1) one-time sale of branded IVD kits to hospitals and diagnostic companies; (2) OEM contract manufacturing of lateral flow tests (CRP, D-Dimer, Troponin I, plus Vitamin D and bladder cancer tests in development) under ISO 13485; (3) supply of mycobacterial antigens, recombinant proteins and endotoxin removal resins to research institutions and biopharma; and (4) licensing-style exclusive distribution of EndoTrap products globally. Pricing is quotation-based across all channels (sales@lionex.de) and is not publicly disclosed. Customer segments span large diagnostic companies, distributors, research institutions, universities and hospitals across all continents, with named distributors including Thermo Fisher/PRIONICS in Switzerland and NPO NanoChimSyntez in Russia.

The company is led by founder Prof. Dr. Mahavir Singh as Executive Director and operates as a tightly held GmbH with no disclosed institutional investors, no parent company, no subsidiaries, and no disclosed funding rounds. Its non-dilutive growth capital comes from participation in at least 14 EU-funded research consortia (EMI-TB, EURIPRED, RAPP-ID with Janssen, POCKET with Ghent/IMEC, TRANSVAC, BactiVax, TESTOMETIC, DIPROMON, IP4Plasma, KeimOUT, Multi-WAP, FluoResYst, NANOKANAL and others) coordinated by the European Commission, WHO, FIND, BMBF and BMWi, which simultaneously generate IP, talent, publications and commercial pipeline assets.

Short descriptiontext

LIONEX is a private German biotech (Braunschweig) that develops and manufactures ISO 13485-certified IVD kits, recombinant antigens and OEM lateral flow tests, anchored by the LIOFeron TB/LTBI IGRA, LIODetect rapid tests and exclusive EndoTrap endotoxin removal resins. It sells globally via direct B2B to diagnostic companies, hospitals, universities and research institutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBraunschweig, Germany
HQ citystring
Braunschweig
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in-vitro diagnostics, tuberculosis diagnostics, endotoxin removal, recombinant antigens, lateral flow tests
Industry3 codes
PRIMARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAOAH
Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In-Vitro Diagnostics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1IVD Products Sales
TypeOne Time License
Description

Sale of In-Vitro Diagnostic products including LIOFeron TB/LTBI IGRA kits, LIODetect rapid tests (CRP, D-Dimer, Troponin I, TB-ST), COVID-19 tests, and other diagnostic kits for professional use.

lionex.de
2OEM Manufacturing
TypeOne Time License
Description

Contract manufacturing of lateral flow tests for partner companies. Products include CRP tests, D-Dimer tests, Troponin I tests, Vitamin D tests (in development), and urinary bladder cancer tests. All manufacturing done in Germany under ISO 13485 conditions.

lionex.de
3Research Products
TypeOne Time License
Description

Sale of research-use recombinant proteins, mycobacterial antigens, and endotoxin removal products (EndoTrap, EndoGrade Ovalbumin) to research institutions and companies worldwide.

lionex.de
4Endotoxin Removal Products
TypeOne Time License
Description

Sale of EndoTrap family products (EndoTrap HD, EndoTrap red) and EndoGrade Ovalbumin for endotoxin removal from proteins, antibodies, vaccines, nucleic acids, and other biological samples.

lionex.de
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1LIOFeron
Description

IGRA (Interferon Gamma Release Assay) diagnostic test for diagnosing Latent TB Infection (LTBI)/TB, consisting of human blood stimulation tubes and human IFN-gamma ELISA kit.

lionex.de
+3 more records
Core offering1 text field

Lionex develops, manufactures, and sells in-vitro diagnostic (IVD) kits (primarily tuberculosis and infectious disease rapid and ELISA tests), endotoxin removal affinity resins (EndoTrap), recombinant mycobacterial antigens and research proteins, and provides OEM contract manufacturing of lateral flow tests. The company also offers a standalone software for automated ELISA result analysis. All products are manufactured in Germany under ISO 13485 certified conditions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • LIODetect TB-ST showed ~98% specificity and ~65% sensitivity in clinical studies
+3 more records
Product overview1 text field

Lionex Diagnostics & Therapeutics is a German biotech company offering a diversified portfolio of in vitro diagnostic products and research reagents. The core offerings include: (1) LIOFeron® TB/LTBI, a novel IGRA test for tuberculosis diagnosis; (2) the LIODetect® family of rapid lateral flow tests including TB-ST, CRP, D-Dimer, Troponin I, and COVID-19 tests; (3) EndoTrap® HD and EndoTrap® red endotoxin removal resins for biomanufacturing; (4) TUB IgG/IgA ELISA kits; (5) mycobacterial antigens and recombinant proteins for research; and (6) OEM manufacturing of lateral flow tests. The company also offers the LIOFeron® stand-alone software for ELISA result analysis. Products are manufactured under ISO 13485 certification at the company's Braunschweig, Germany facility.

Product and service17 records
1LIOFeron TB/LTBI IGRA Test
CategoryIn-Vitro Diagnostics (TB)
Description

A 2-component Interferon Gamma Release Assay (IGRA) kit for diagnosing Latent Tuberculosis Infection (LTBI) and TB, consisting of Human Blood Stimulation Tubes containing proprietary TB antigens (ESAT6, CFP10, TB 7.7) and Human IFN-γ ELISA for quantifying the interferon-gamma response. Intended for professional in vitro diagnostic use.

2LIODetect TB-ST Tuberculosis Rapid Test
CategoryIn-Vitro Diagnostics (TB)
Description

Rapid lateral flow test for qualitative detection of IgG, IgA and IgM antibodies to Mycobacterium tuberculosis in serum, plasma or whole blood with results within 20 minutes; demonstrates approximately 98% specificity and 65% sensitivity.

3LIODetect CRP Rapid Tests
CategoryIn-Vitro Diagnostics (Cardiac/Inflammatory Markers)
Description

Semi-quantitative rapid tests for detection of C-reactive protein (CRP) in serum, plasma or whole blood within 5-10 minutes, available in two variants (CRP 10-30 and CRP 10-60). For professional in vitro diagnostic use.

4LIODetect D-Dimer Rapid Test
CategoryIn-Vitro Diagnostics (Cardiac/Inflammatory Markers)
Description

Rapid visual test for qualitative detection of D-dimer in plasma or whole blood within 10-15 minutes, intended to aid in the diagnosis of thrombotic events. For professional in vitro diagnostic use.

5LIODetect Troponin I Rapid Test
CategoryIn-Vitro Diagnostics (Cardiac/Inflammatory Markers)
Description

Visual rapid test for qualitative detection of Troponin I in whole blood, plasma and serum samples within 10-15 minutes, intended to support diagnosis of acute myocardial infarction (AMI). For professional in vitro diagnostic use.

6COVID-19 Rapid Tests
CategoryIn-Vitro Diagnostics (Infectious Disease)
Description

Series of rapid tests for SARS-CoV-2 including IgG antibody detection, IgM antibody detection, and antigen detection (LD COVID-19 IgG, LD COVID-19 IgM, COVID-19 Ag Rapid Test). For professional in vitro diagnostic use.

7EndoTrap HD
CategoryBioprocessing Reagents (Endotoxin Removal)
Description

Affinity chromatography resin for endotoxin (LPS) removal from proteins, antibodies, vaccines, nucleic acids and other biological samples; usable in column or batch mode, with >5,000,000 EU/ml binding capacity, >99.99% LPS removal, >95% sample recovery, and reusable up to 10 times.

8EndoTrap red
CategoryBioprocessing Reagents (Endotoxin Removal)
Description

Affinity matrix for endotoxin removal from proteins, antibodies, cell extracts and nucleic acids; compatible with buffers containing calcium chelators, with >2,000,000 EU/ml binding capacity and reusable at least 3 times.

9EndoGrade Ovalbumin
CategoryResearch Reagents
Description

Endotoxin-free ovalbumin product intended for use in vaccine development and immunological research.

10TUB IgG ELISA
CategoryIn-Vitro Diagnostics (TB ELISA)
Description

Microtiter plate-based enzyme immunoassay for quantitative detection of human IgG antibodies to Mycobacterium tuberculosis in serum, plasma or CSF within 100 minutes. For professional in vitro diagnostic use.

11TUB IgA ELISA
CategoryIn-Vitro Diagnostics (TB ELISA)
Description

Microtiter plate-based enzyme immunoassay for quantitative detection of human IgA antibodies to Mycobacterium tuberculosis in serum, plasma or CSF within 100 minutes. For professional in vitro diagnostic use.

12TUB IgM ELISA
CategoryIn-Vitro Diagnostics (TB ELISA)
Description

Microtiter plate-based enzyme immunoassay for the detection of IgM antibodies to Mycobacterium tuberculosis, evidenced by downloadable product manuals on the LIONEX website. For professional in vitro diagnostic use.

13Mycobacterial Antigens (Research Catalog)
CategoryResearch Reagents (Proteins/Antigens)
Description

Large catalog of highly purified, endotoxin-free recombinant and native antigens of Mycobacterium tuberculosis (including ESAT6, CFP10, Ag85B, 16kD, ALADH, HSP70, HSP65, MPT64, LAM and others) for use in TB and mycobacterial disease research and vaccine development.

14LIOSpot TB human
CategoryIn-Vitro Diagnostics (TB)
Description

ELISPOT test capable of differentiating between latent TB infection (LTBI) and active TB, protected by international patents of LIONEX.

15LIOFeron Software
CategorySoftware
Description

Stand-alone software for automatic analysis of LIOFeron TB/LTBI ELISA results, with options for direct import of raw data from various ELISA readers (including the DS2 automated platform) in .csv/.txt formats.

16Detect-Clostridium perfringens Beta 2-Toxin Test
CategoryResearch Reagents (Veterinary/Food Safety)
Description

Membrane-based rapid test for detection of Clostridium perfringens Beta 2-Toxin in culture supernatants, intended for research use only.

17OEM Lateral Flow Test Manufacturing
CategoryOEM Manufacturing Services
Description

Contract (OEM) manufacturing of lateral flow rapid tests for partner companies, including CRP, D-Dimer, Troponin I, Vitamin D and urinary bladder cancer tests, produced under ISO 13485 conditions in Germany.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership20 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner in POCKET project for development of low-cost point-of-care TB sensor using silicon nitride chip technology. LIONEX responsible for antibody and antigen development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner in POCKET project for chip fabrication of TB detection sensor.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner in TRANSVAC project coordinated by EVI for accelerating vaccine development through European vaccine research infrastructure.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner in Multi-WAP and DEMO-Multi-WAP projects for multiplexed fiber optic biosensor for waterborne pathogen detection. IIT responsible for sensor array development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner in IP4Plasma project for coordination, valorisation, and market studies in atmospheric pressure plasma technology for medical diagnostics.

6Fraunhofer Institute for Surface Engineering and Thin Films IST
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner in IP4Plasma project for RTD performance of plasma processes development.

lionex.de
7Max Planck Institute for Biophysical Chemistry
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner in KeimOUT project developing rapid detection technology for multi-resistant hospital germs.

lionex.de
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborator in HIV vaccine development with candidate vaccine ready for Phase II trials. LIONEX contributes to research in infectious diseases and cancer therapeutics.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic research partner in Sweden for TB and infectious disease research collaborations.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partner in Mozambique for TB research collaborations.

11NPO NanoChimSyntez
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partner in Russian Federation for distribution of LIONEX products.

lionex.de
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner/客户关系展示 on LIONEX website.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner in IP4Plasma project for plasma system manufacturing.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner in POCKET and FluoResYst projects for microfluidic chip development.

15Life Technologies (Thermo Fisher Scientific/PRIONICS AG)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Partner/distributor in Switzerland for diagnostics products.

lionex.de
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner in BactiVax innovative training network for anti-bacterial vaccine development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Coordinator of DIPROMON project for bladder cancer biomarkers. LIONEX discovers, characterises and produces purified biomarkers.

18Aegirbio
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner in TESTOMETIC project for next generation COVID-19 PoC diagnostic test development.

lionex.de
Strategic tierCoreTypeStrategic or Co-development Partner
Description

RAPP-ID project coordinator for rapid detection of bacteria, mycobacteria, fungi and viruses. LIONEX participates in TB-related research within this consortium.

20Stiftung Tierärztliche Hochschule Hannover
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner in Sero-FaSt-Myho project for Mycoplasma hyopneumoniae serological test development.

lionex.de
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat6 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lionex Diagnostics & Therapeutics

In-Vitro Diagnosticslionex.de

LIONEX is a private German biotech (Braunschweig) that develops and manufactures ISO 13485-certified IVD kits, recombinant antigens and OEM lateral flow tests, anchored by the LIOFeron TB/LTBI IGRA, LIODetect rapid tests and exclusive EndoTrap endotoxin removal resins. It sells globally via direct B2B to diagnostic companies, hospitals, universities and research institutions.

What Lionex Diagnostics & Therapeutics does

LIONEX Diagnostics & Therapeutics GmbH is a privately held German biotech company headquartered in Braunschweig that develops and manufactures in-vitro diagnostic (IVD) products, research reagents and OEM lateral flow assays, with its strategic centre of gravity in tuberculosis (TB) and adjacent infectious disease and cancer biomarker detection. The company operates ISO 13485-certified manufacturing facilities (re-certified December 2024 by TÜV Rheinland) including CAT-I and CAT-II molecular biology laboratories with CAT-III access, and produces highly purified, endotoxin-free recombinant proteins using multiple expression systems (E. coli, insect cells, B. subtilis, Lactococcus lactis, M. smegmatis). Its flagship proprietary assets are the LIOFeron TB/LTBI Interferon Gamma Release Assay (IGRA) — featuring a unique antigen cocktail including alanine dehydrogenase for CD8+ T-cell stimulation — the LIODetect rapid lateral flow family (TB-ST, CRP, D-Dimer, Troponin I, COVID-19 IgG/IgM/Ag), and the patented LIOSpot TB ELISPOT test that differentiates latent from active TB. The company also holds exclusive global manufacturing and distribution rights to the EndoTrap family of endotoxin removal resins (acquired when Hyglos discontinued in December 2017) and offers EndoGrade endotoxin-free ovalbumin for vaccine research.

LIONEX monetizes through four distinct revenue streams: (1) one-time sale of branded IVD kits to hospitals and diagnostic companies; (2) OEM contract manufacturing of lateral flow tests (CRP, D-Dimer, Troponin I, plus Vitamin D and bladder cancer tests in development) under ISO 13485; (3) supply of mycobacterial antigens, recombinant proteins and endotoxin removal resins to research institutions and biopharma; and (4) licensing-style exclusive distribution of EndoTrap products globally. Pricing is quotation-based across all channels (sales@lionex.de) and is not publicly disclosed. Customer segments span large diagnostic companies, distributors, research institutions, universities and hospitals across all continents, with named distributors including Thermo Fisher/PRIONICS in Switzerland and NPO NanoChimSyntez in Russia.

The company is led by founder Prof. Dr. Mahavir Singh as Executive Director and operates as a tightly held GmbH with no disclosed institutional investors, no parent company, no subsidiaries, and no disclosed funding rounds. Its non-dilutive growth capital comes from participation in at least 14 EU-funded research consortia (EMI-TB, EURIPRED, RAPP-ID with Janssen, POCKET with Ghent/IMEC, TRANSVAC, BactiVax, TESTOMETIC, DIPROMON, IP4Plasma, KeimOUT, Multi-WAP, FluoResYst, NANOKANAL and others) coordinated by the European Commission, WHO, FIND, BMBF and BMWi, which simultaneously generate IP, talent, publications and commercial pipeline assets.

Lionex Diagnostics & Therapeutics firmographics

Firmographics
Name
Lionex Diagnostics & Therapeutics
Legal name
LIONEX GmbH
Website
https://lionex.de
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
LIONEX is a private German biotech (Braunschweig) that develops and manufactures ISO 13485-certified IVD kits, recombinant antigens and OEM lateral flow tests, anchored by the LIOFeron TB/LTBI IGRA, LIODetect rapid tests and exclusive EndoTrap endotoxin removal resins. It sells globally via direct B2B to diagnostic companies, hospitals, universities and research institutions.
Ownership category
akta.pro rank

Lionex Diagnostics & Therapeutics industry classification

Industry
Product category
In-Vitro Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Equipment and Supplies Manufacturing (3391)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAOAH
Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)

Keywords

  • In-vitro diagnostics
  • Tuberculosis diagnostics
  • Endotoxin removal
  • Recombinant antigens
  • Lateral flow tests

Where Lionex Diagnostics & Therapeutics is headquartered

Location

Headquarters

HQ city
Braunschweig
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Lionex Diagnostics & Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. IVD Products Sales: Sale of In-Vitro Diagnostic products including LIOFeron TB/LTBI IGRA kits, LIODetect rapid tests (CRP, D-Dimer, Troponin I, TB-ST), COVID-19 tests, and other diagnostic kits for professional use.
  2. OEM Manufacturing: Contract manufacturing of lateral flow tests for partner companies. Products include CRP tests, D-Dimer tests, Troponin I tests, Vitamin D tests (in development), and urinary bladder cancer tests. All manufacturing done in Germany under ISO 13485 conditions.
  3. Research Products: Sale of research-use recombinant proteins, mycobacterial antigens, and endotoxin removal products (EndoTrap, EndoGrade Ovalbumin) to research institutions and companies worldwide.
  4. Endotoxin Removal Products: Sale of EndoTrap family products (EndoTrap HD, EndoTrap red) and EndoGrade Ovalbumin for endotoxin removal from proteins, antibodies, vaccines, nucleic acids, and other biological samples.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Lionex Diagnostics & Therapeutics product offering

Product offering

Core offering

Lionex develops, manufactures, and sells in-vitro diagnostic (IVD) kits (primarily tuberculosis and infectious disease rapid and ELISA tests), endotoxin removal affinity resins (EndoTrap), recombinant mycobacterial antigens and research proteins, and provides OEM contract manufacturing of lateral flow tests. The company also offers a standalone software for automated ELISA result analysis. All products are manufactured in Germany under ISO 13485 certified conditions.

Product overview

Lionex Diagnostics & Therapeutics is a German biotech company offering a diversified portfolio of in vitro diagnostic products and research reagents. The core offerings include: (1) LIOFeron® TB/LTBI, a novel IGRA test for tuberculosis diagnosis; (2) the LIODetect® family of rapid lateral flow tests including TB-ST, CRP, D-Dimer, Troponin I, and COVID-19 tests; (3) EndoTrap® HD and EndoTrap® red endotoxin removal resins for biomanufacturing; (4) TUB IgG/IgA ELISA kits; (5) mycobacterial antigens and recombinant proteins for research; and (6) OEM manufacturing of lateral flow tests. The company also offers the LIOFeron® stand-alone software for ELISA result analysis. Products are manufactured under ISO 13485 certification at the company's Braunschweig, Germany facility.

Differentiator

Problem solved

Functional benefit

Brands

  • LIOFeron: IGRA (Interferon Gamma Release Assay) diagnostic test for diagnosing Latent TB Infection (LTBI)/TB, consisting of human blood stimulation tubes and human IFN-gamma ELISA kit.
  • LIODetect
  • EndoTrap
  • EndoGrade

Products and services

  • LIOFeron TB/LTBI IGRA Test A 2-component Interferon Gamma Release Assay (IGRA) kit for diagnosing Latent Tuberculosis Infection (LTBI) and TB, consisting of Human Blood Stimulation Tubes containing proprietary TB antigens (ESAT6, CFP10, TB 7.7) and Human IFN-γ ELISA for quantifying the interferon-gamma response. Intended for professional in vitro diagnostic use.
  • LIODetect TB-ST Tuberculosis Rapid Test Rapid lateral flow test for qualitative detection of IgG, IgA and IgM antibodies to Mycobacterium tuberculosis in serum, plasma or whole blood with results within 20 minutes; demonstrates approximately 98% specificity and 65% sensitivity.
  • LIODetect CRP Rapid Tests Semi-quantitative rapid tests for detection of C-reactive protein (CRP) in serum, plasma or whole blood within 5-10 minutes, available in two variants (CRP 10-30 and CRP 10-60). For professional in vitro diagnostic use.
  • LIODetect D-Dimer Rapid Test Rapid visual test for qualitative detection of D-dimer in plasma or whole blood within 10-15 minutes, intended to aid in the diagnosis of thrombotic events. For professional in vitro diagnostic use.
  • LIODetect Troponin I Rapid Test Visual rapid test for qualitative detection of Troponin I in whole blood, plasma and serum samples within 10-15 minutes, intended to support diagnosis of acute myocardial infarction (AMI). For professional in vitro diagnostic use.
  • COVID-19 Rapid Tests Series of rapid tests for SARS-CoV-2 including IgG antibody detection, IgM antibody detection, and antigen detection (LD COVID-19 IgG, LD COVID-19 IgM, COVID-19 Ag Rapid Test). For professional in vitro diagnostic use.
  • EndoTrap HD Affinity chromatography resin for endotoxin (LPS) removal from proteins, antibodies, vaccines, nucleic acids and other biological samples; usable in column or batch mode, with >5,000,000 EU/ml binding capacity, >99.99% LPS removal, >95% sample recovery, and reusable up to 10 times.
  • EndoTrap red Affinity matrix for endotoxin removal from proteins, antibodies, cell extracts and nucleic acids; compatible with buffers containing calcium chelators, with >2,000,000 EU/ml binding capacity and reusable at least 3 times.
  • EndoGrade Ovalbumin Endotoxin-free ovalbumin product intended for use in vaccine development and immunological research.
  • TUB IgG ELISA Microtiter plate-based enzyme immunoassay for quantitative detection of human IgG antibodies to Mycobacterium tuberculosis in serum, plasma or CSF within 100 minutes. For professional in vitro diagnostic use.
  • TUB IgA ELISA Microtiter plate-based enzyme immunoassay for quantitative detection of human IgA antibodies to Mycobacterium tuberculosis in serum, plasma or CSF within 100 minutes. For professional in vitro diagnostic use.
  • TUB IgM ELISA Microtiter plate-based enzyme immunoassay for the detection of IgM antibodies to Mycobacterium tuberculosis, evidenced by downloadable product manuals on the LIONEX website. For professional in vitro diagnostic use.
  • Mycobacterial Antigens (Research Catalog) Large catalog of highly purified, endotoxin-free recombinant and native antigens of Mycobacterium tuberculosis (including ESAT6, CFP10, Ag85B, 16kD, ALADH, HSP70, HSP65, MPT64, LAM and others) for use in TB and mycobacterial disease research and vaccine development.
  • LIOSpot TB human ELISPOT test capable of differentiating between latent TB infection (LTBI) and active TB, protected by international patents of LIONEX.
  • LIOFeron Software Stand-alone software for automatic analysis of LIOFeron TB/LTBI ELISA results, with options for direct import of raw data from various ELISA readers (including the DS2 automated platform) in .csv/.txt formats.
  • Detect-Clostridium perfringens Beta 2-Toxin Test Membrane-based rapid test for detection of Clostridium perfringens Beta 2-Toxin in culture supernatants, intended for research use only.
  • OEM Lateral Flow Test Manufacturing Contract (OEM) manufacturing of lateral flow rapid tests for partner companies, including CRP, D-Dimer, Troponin I, Vitamin D and urinary bladder cancer tests, produced under ISO 13485 conditions in Germany.

Quantifiable outcome

  • LIODetect TB-ST showed ~98% specificity and ~65% sensitivity in clinical studies
  • +3 more outcomes

Companies that use Lionex Diagnostics & Therapeutics

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Lionex Diagnostics & Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature6 records

Lionex Diagnostics & Therapeutics partnerships and signals

Strategic signal

Partnerships

20 partnerships are on record, tiered core and minor.

  • Ghent University – Photonic GroupcoreStrategic or Co-development PartnerPartner in POCKET project for development of low-cost point-of-care TB sensor using silicon nitride chip technology. LIONEX responsible for antibody and antigen development.
  • IMECcoreStrategic or Co-development PartnerPartner in POCKET project for chip fabrication of TB detection sensor.
  • European Vaccine Initiative (EVI)coreStrategic or Co-development PartnerPartner in TRANSVAC project coordinated by EVI for accelerating vaccine development through European vaccine research infrastructure.
  • IIT MadrascoreStrategic or Co-development PartnerPartner in Multi-WAP and DEMO-Multi-WAP projects for multiplexed fiber optic biosensor for waterborne pathogen detection. IIT responsible for sensor array development.
  • Spinverse LtdminorStrategic or Co-development PartnerPartner in IP4Plasma project for coordination, valorisation, and market studies in atmospheric pressure plasma technology for medical diagnostics.
  • Fraunhofer Institute for Surface Engineering and Thin Films ISTminorStrategic or Co-development PartnerPartner in IP4Plasma project for RTD performance of plasma processes development.
  • Max Planck Institute for Biophysical ChemistryminorStrategic or Co-development PartnerPartner in KeimOUT project developing rapid detection technology for multi-resistant hospital germs.
  • Kings College LondoncoreStrategic or Co-development PartnerCollaborator in HIV vaccine development with candidate vaccine ready for Phase II trials. LIONEX contributes to research in infectious diseases and cancer therapeutics.
  • Karolinska InstitutetminorStrategic or Co-development PartnerAcademic research partner in Sweden for TB and infectious disease research collaborations.
  • Universidade Eduardo MondlaneminorStrategic or Co-development PartnerAcademic partner in Mozambique for TB research collaborations.
  • NPO NanoChimSyntezminorChannel Partner/ Reseller/ DistributorPartner in Russian Federation for distribution of LIONEX products.
  • Locus BiosciencesminorStrategic or Co-development PartnerPartner/客户关系展示 on LIONEX website.
  • SOFTAL Corona & Plasma GmbHminorStrategic or Co-development PartnerPartner in IP4Plasma project for plasma system manufacturing.
  • Microfluidic ChipShopminorStrategic or Co-development PartnerPartner in POCKET and FluoResYst projects for microfluidic chip development.
  • Life Technologies (Thermo Fisher Scientific/PRIONICS AG)coreChannel Partner/ Reseller/ DistributorPartner/distributor in Switzerland for diagnostics products.
  • University College DublinminorStrategic or Co-development PartnerPartner in BactiVax innovative training network for anti-bacterial vaccine development.
  • University of SurreycoreStrategic or Co-development PartnerCoordinator of DIPROMON project for bladder cancer biomarkers. LIONEX discovers, characterises and produces purified biomarkers.
  • AegirbiominorStrategic or Co-development PartnerPartner in TESTOMETIC project for next generation COVID-19 PoC diagnostic test development.
  • Janssen Research & DevelopmentcoreStrategic or Co-development PartnerRAPP-ID project coordinator for rapid detection of bacteria, mycobacteria, fungi and viruses. LIONEX participates in TB-related research within this consortium.
  • Stiftung Tierärztliche Hochschule HannoverminorStrategic or Co-development PartnerPartner in Sero-FaSt-Myho project for Mycoplasma hyopneumoniae serological test development.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Lionex Diagnostics & Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat6 records

Key highlights6 records

Customer concentration

Lionex Diagnostics & Therapeutics social profiles

Digital presence

Lionex Diagnostics & Therapeutics compliance and trust

Trust signal

Compliance2 records

Lionex Diagnostics & Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lionex Diagnostics & Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Lionex Diagnostics & Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lionex Diagnostics & Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lionex Diagnostics & Therapeutics

What does Lionex Diagnostics & Therapeutics do?

Lionex develops, manufactures, and sells in-vitro diagnostic (IVD) kits (primarily tuberculosis and infectious disease rapid and ELISA tests), endotoxin removal affinity resins (EndoTrap), recombinant mycobacterial antigens and research proteins, and provides OEM contract manufacturing of lateral flow tests. The company also offers a standalone software for automated ELISA result analysis. All products are manufactured in Germany under ISO 13485 certified conditions.

Is Lionex Diagnostics & Therapeutics a public or private company?

Lionex Diagnostics & Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Lionex Diagnostics & Therapeutics founded?

Lionex Diagnostics & Therapeutics was founded in -1. It employs 11 to 50 people.

Where is Lionex Diagnostics & Therapeutics based?

Lionex Diagnostics & Therapeutics is headquartered in Braunschweig, Germany, in the Europe region.

How does Lionex Diagnostics & Therapeutics make money?

Four revenue lines are on record. IVD Products Sales are the primary driver. The others are OEM Manufacturing, research Products and endotoxin Removal Products.

Does Lionex Diagnostics & Therapeutics have an API?

No public API is recorded for Lionex Diagnostics & Therapeutics.

What industry is Lionex Diagnostics & Therapeutics in?

Lionex Diagnostics & Therapeutics's product category is In-Vitro Diagnostics. Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAHAOAH, Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals